Education
About Us
Working with TipRanks
Follow Us
Biorestorative Therapies, Inc. (BRTX)
:BRTX
Top Page
BioRestorative Therapies
(NASDAQ:BRTX)
Rating:48Neutral
Price Target:―
Positive Factors
Market Position
BRTX-100 is the first and only MSC so far to move into this region of the spine, representing a potential advantage over other MSC products due to its hypoxic conditioning.
Regulatory Approval
BRTX-100 received Fast Track designation from the FDA, which could expedite the development process.
Safety Profile
No serious adverse events were reported in the ongoing trial, indicating a positive safety profile for BRTX-100.
Negative Factors
Financial Performance
The company reported a net loss of ($4.8M) and revenue of $25k.
Market Competition
Increasing regulatory acceptance of MSCs is noted, with other companies making advancements in this space.
BioRestorative Therapies (BRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.01M
Dividend YieldN/A
Average Volume (3M)29.84K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth175.03%
EPS Growth55.34%
CountryUS
Employees11
SectorHealthcare
Sector Strength43
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.64
Shares Outstanding7,504,780
10 Day Avg. Volume38,442
30 Day Avg. Volume29,843
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-1.37
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue8.08
Enterprise Value/Gross Profit30.15
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$13.00Price Target Upside733.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
BioRestorative Therapies Business Overview & Revenue Model
Company DescriptionBioRestorative Therapies (BRTX) is a biotechnology company focused on the development of innovative therapeutic solutions using cell and tissue therapies. The company operates primarily in the field of regenerative medicine, with a particular emphasis on stem cell-based therapies for the treatment of chronic lumbar disc disease and metabolic disorders. Its core products include BRTX-100, a stem cell-based therapeutic targeting disc/spine disease, and ThermoStem, a program focused on metabolic disorders including obesity and diabetes.
How the Company Makes MoneyBioRestorative Therapies generates revenue through the development and commercialization of its proprietary cell and tissue-based therapeutic products. The company aims to earn revenue by advancing its clinical programs through various stages of regulatory approval, ultimately leading to product commercialization and sales. Key revenue streams include potential licensing agreements, strategic partnerships, and collaborations with pharmaceutical companies interested in its therapies. Additionally, BRTX may secure funding from grants and research subsidies as it progresses its clinical trials and expands its research initiatives. However, being a biotechnology company in the developmental stage, BioRestorative Therapies may also rely on equity financing and other forms of investment to support its operations until its therapies are fully developed and marketed.
BioRestorative Therapies Financial Statement Overview
Summary
BioRestorative Therapies is in a challenging financial position with consistent net losses and negative cash flows, despite some revenue growth. While the balance sheet shows reduced leverage and improved equity, the company's ability to generate cash and achieve profitability remains a significant concern. Continued focus on cost management and operational efficiency will be crucial for financial stability.Income Statement
BioRestorative Therapies shows a significant increase in revenue year-over-year, but it remains small in absolute terms. Despite this, the company struggles with negative profitability metrics, including persistent net losses and negative EBIT and EBITDA margins, indicating ongoing operational challenges and high costs relative to revenue.30
Negative
Balance Sheet
The company has improved its equity position with positive stockholders' equity, and it has no current total debt, reducing financial risk. However, the frequent large net losses impact the overall asset quality, and the equity ratio has been declining, signaling a need for better asset management.40
Negative
Cash Flow
Operating cash flow has been consistently negative, reflecting ongoing cash outflows from operations. While free cash flow has seen slight improvement, it remains negative, indicating cash burn. The reliance on financing activities to support cash needs is evident, which may not be sustainable long-term without improved operational cash generation.35
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 391.00K | 401.00K | 145.80K | 119.80K | 46.00K | 77.00K | Gross Profit |
| 360.02K | 372.93K | 145.80K | -160.87K | -159.21K | 77.00K | EBIT |
| -12.25M | -11.56M | -15.22M | -18.97M | -26.31M | -2.75M | EBITDA |
| -12.11M | -11.37M | -15.06M | -18.85M | -26.22M | -9.48M | Net Income Common Stockholders |
| -12.10M | -8.98M | -10.42M | -18.02M | -29.94M | -12.25M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 12.37M | 10.73M | 11.07M | 14.75M | 21.03M | 3.06M | Total Assets |
| 14.08M | 12.28M | 12.61M | 16.43M | 22.45M | 4.35M | Total Debt |
| 268.36K | 0.00 | 162.32K | 301.64K | 670.70K | 4.79M | Net Debt |
| -1.57M | -547.89K | -722.06K | -1.37M | -20.36M | 1.73M | Total Liabilities |
| 593.93K | 3.75M | 2.61M | 602.62K | 856.50K | 5.68M | Stockholders Equity |
| 13.49M | 8.53M | 10.00M | 15.83M | 21.60M | -1.33M |
| Cash Flow | Free Cash Flow | ||||
| -8.80M | -8.34M | -6.60M | -6.31M | -3.36M | -1.96M | Operating Cash Flow |
| -8.69M | -8.23M | -6.43M | -5.87M | -3.33M | -1.96M | Investing Cash Flow |
| 7.81M | 514.53K | 3.25M | -13.48M | -30.66K | 0.00 | Financing Cash Flow |
| 953.56K | 7.38M | 2.35M | 0.00 | 21.32M | 5.03M |
BioRestorative Therapies Technical Analysis
Negative
1.56
Price Trends
1.74
Negative
1.84
Negative
1.71
Negative
Market Momentum
-0.05
Positive
39.87
Neutral
10.53
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 1.56 is below the 20-day moving average (MA) of 1.72, below the 50-day MA of 1.74, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 39.87 is Neutral, neither overbought nor oversold. The STOCH value of 10.53 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.
BioRestorative Therapies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.06 | -43.57% | 2.81% | 16.81% | -0.12% | |
48 Neutral | $12.01M | ― | -117.16% | ― | 175.03% | 55.34% | |
42 Neutral | $8.78M | ― | -76.12% | ― | ― | 81.71% | |
41 Neutral | $7.76M | ― | -397.54% | ― | ― | 24.16% | |
41 Neutral | $14.32M | ― | -89.73% | ― | -100.00% | -292.59% | |
40 Underperform | $15.41M | ― | -106.05% | ― | ― | 9.46% | |
34 Underperform | $11.80M | ― | -174.66% | ― | ― | 38.53% |
* Healthcare Sector Average
Performance Comparison
BRTX
BioRestorative Therapies
1.60
0.28
21.21%
IMNN
Imunon
0.42
-1.03
-71.03%
MEIP
MEI Pharma
2.20
-0.94
-29.94%
PHIO
Phio Pharmaceuticals
1.84
-5.07
-73.37%
COCP
Cocrystal Pharma
1.46
-0.61
-29.47%
INAB
IN8bio
0.13
-0.91
-87.50%
BioRestorative Therapies Earnings Call Summary
Earnings Call Date:May 14, 2025
(Q1-2025)
| % Change Since: -8.77%|
Next Earnings Date:Aug 19, 2025
Earnings Call Sentiment Neutral
BioRestorative Therapies demonstrated significant progress with their BRTX-100 program, achieving FDA Fast Track designation and clearance for a new clinical trial, positioning the company strongly in the cell-based therapy market. However, financial challenges and a decline in revenue remain concerns.Q1-2025 Updates
Positive Updates
FDA Fast Track Designation for BRTX-100
BioRestorative Therapies received FDA Fast Track designation for their BRTX-100 program targeting chronic lumbar disc disease, facilitating development and expediting review processes.
FDA Clearance for Phase II Clinical Trial in cCDP
The FDA cleared BioRestorative's investigational drug application for a Phase II clinical trial of BRTX-100 in chronic cervical discogenic pain, marking it as the first stem cell-based product candidate to be evaluated in cervical degeneration disc disease.
Strong Financial Position
The company ended the quarter with $9.1 million in cash, cash equivalents, and marketable securities, with no outstanding debt.
Positive Preliminary Data for BRTX-100
Preliminary blinded data shows positive trends in safety and efficacy for BRTX-100 in treating chronic lumbar disc disease, with no serious adverse events reported.
Expansion of ThermoStem IP Portfolio
BioRestorative expanded its intellectual property estate for ThermoStem, covering both U.S. and international markets, to protect its potential treatments for obesity and metabolic disorders.
Negative Updates
Decrease in First Quarter Revenues
First quarter revenues decreased to $25,000 from $35,000 in the same period last year.
Increased Net Loss
Net loss for the first quarter of 2025 was $5.3 million, or $0.64 per share, compared to $2.2 million, or $0.33 per share, for the first quarter of 2024.
Higher Operating Loss
Operating loss increased to $4.8 million in Q1 2025 from $4.1 million in the same period of 2024.
Challenges in Patient Enrollment
Patient enrollment for clinical trials is challenging due to strict criteria, though efforts are being made to improve recruitment strategies.
Company Guidance
During the first quarter of 2025, BioRestorative Therapies provided guidance on various financial and operational metrics. The company reported a revenue of approximately $25,000, a decrease from $35,000 in the same period the previous year, but highlighted $150,000 in deferred revenues, indicating timing differences in revenue recognition. The loss from operations rose to $4.8 million from $4.1 million in the first quarter of 2024, and the net loss increased to $5.3 million or $0.64 per share, compared to $2.2 million or $0.33 per share in the prior year, primarily due to a previous gain on warrant exchange. Despite the increased losses, the company maintained a solid financial position with $9.1 million in cash, cash equivalents, and marketable securities, and no outstanding debt. Operationally, the company achieved two significant FDA milestones for its lead candidate, BRTX-100, including a Fast Track designation for its chronic lumbar disc disease program and clearance for a Phase II trial in chronic cervical discogenic pain, while continuing to advance its preclinical ThermoStem program targeting obesity and metabolic disorders.BioRestorative Therapies Corporate Events
Regulatory Filings and Compliance
BioRestorative Clarifies Recent Press Release Details
Neutral
Mar 27, 2025
BioRestorative Therapies has released a statement clarifying that the information in their recent press release is being furnished and not filed, and will not be incorporated into any registration statement unless specifically identified. The company emphasizes that this does not constitute a determination or admission that the information is material or complete, nor should it be considered by investors for making investment decisions.
Regulatory Filings and Compliance
BioRestorative Therapies Issues Regulation FD Disclosure
Neutral
Feb 10, 2025
The news release does not contain specific information about BioRestorative Therapies’ industry, primary products or services, or market focus. The release appears to reference a Current Report on Form 8-K without providing substantial details about the company’s operations or implications for stakeholders.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.